or Try an Advanced Search...

    Vascular And Metabolic Diseases Stocks List

    Symbol Grade Name % Change
    MDGL A Madrigal Pharmaceuticals, Inc. 23.23
    LIXT D Lixte Biotechnology Holdings, Inc. -4.27
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Metabolic Disease Biomarker Technology Biomarkers Biotechnology Cancer Cancer Center Cholesterol Clinical Development Degenerative Disease Drug Discovery Dyslipidemia Endocrine System Glands Hypercholesterolemia Hyperlipidemia Immune Checkpoint Lipid Medication National Cancer Institute Neurodegenerative Diseases

    Related ETFs - A few ETFs which own one or more of the above listed Vascular And Metabolic Diseases stocks.

    Symbol Grade Name Weight
    SURI A Simplify Exchange Traded Funds Simplify Propel Opportunities ETF 3.53
    XBI B SPDR S&P Biotech ETF 1.38
    GURU A Global X Top Guru Holdings Index ETF 1.21
    BBP A BioShares Biotechnology Products Fund 1.09
    HRTS D Tema Cardiovascular and Metabolic ETF 0.95
    View all Vascular And Metabolic Diseases ETFs...
    Compare ETFs
    Compare BBP to HRTS Compare SURI to HRTS Compare XBI to GURU

        Vascular And Metabolic Diseases Stocks Recent News

        Date Stock Title
        Nov 2 MDGL Analysts Just Made A Notable Upgrade To Their Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Forecasts
        Nov 1 MDGL Madrigal Pharmaceuticals stock jumps on MASH drug hopes
        Nov 1 MDGL Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH
        Nov 1 MDGL Stocks that hedge funds moved from long to short in August - Jefferies
        Nov 1 MDGL Madrigal Q3 Earnings Beat, NASH Drug Sales Drive Top Line, Stock Up
        Nov 1 MDGL Madrigal Pharmaceuticals Inc (MDGL) Q3 2024 Earnings Call Highlights: Strong Sales and ...
        Oct 31 MDGL Madrigal Pharmaceuticals, Inc. (MDGL) Q3 2024 Earnings Call Transcript
        Oct 31 MDGL Madrigal stock jumps 13% after Rezdiffra Q3 sales beat estimates
        Oct 31 MDGL Madrigal Pharmaceuticals, Inc. 2024 Q3 - Results - Earnings Call Presentation
        Oct 31 MDGL Madrigal: Q3 Earnings Snapshot
        Oct 31 MDGL Madrigal Pharmaceuticals GAAP EPS of -$4.92 beats by $2.00, revenue of $62.2M beats by $27.79M
        Oct 31 MDGL Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates
        Oct 30 MDGL Madrigal Pharmaceuticals Q3 2024 Earnings Preview
        Oct 30 MDGL Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting®
        Oct 29 LIXT Why VF Corp Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket
        Oct 28 MDGL Madrigal Pharmaceuticals: Looking To Finally Establish A Position Around The Q3 Earnings
        Related Industries: Biotechnology
        Related Stock Lists: Metabolic Disease Biomarker Technology Biomarkers Biotechnology Cancer Cancer Center Cholesterol Clinical Development Degenerative Disease Drug Discovery Dyslipidemia Endocrine System Glands Hypercholesterolemia Hyperlipidemia Immune Checkpoint Lipid Medication National Cancer Institute Neurodegenerative Diseases
        Vascular And Metabolic Diseases

        Vascular and metabolic diseases are conditions that affect the body's blood vessels and metabolism. Examples of vascular diseases include stroke, peripheral artery disease, and aneurysms. Metabolic diseases include diabetes, obesity, and metabolic syndrome. These diseases can lead to serious health complications, including heart attack, stroke, and kidney failure. Treatment for these conditions typically involves lifestyle changes, medications, and in some cases, surgery.

        Browse All Tags